MDT

85.46

-0.37%↓

113.1

+0.48%↑

VEEV

175.09

-1.25%↓

HQY

82.12

-0.07%↓

CSBR

5.63

-2.26%↓

MDT

85.46

-0.37%↓

113.1

+0.48%↑

VEEV

175.09

-1.25%↓

HQY

82.12

-0.07%↓

CSBR

5.63

-2.26%↓

MDT

85.46

-0.37%↓

113.1

+0.48%↑

VEEV

175.09

-1.25%↓

HQY

82.12

-0.07%↓

CSBR

5.63

-2.26%↓

MDT

85.46

-0.37%↓

113.1

+0.48%↑

VEEV

175.09

-1.25%↓

HQY

82.12

-0.07%↓

CSBR

5.63

-2.26%↓

MDT

85.46

-0.37%↓

113.1

+0.48%↑

VEEV

175.09

-1.25%↓

HQY

82.12

-0.07%↓

CSBR

5.63

-2.26%↓

Home・Akciju saraksts・CytomX Therapeutics Inc

CytomX Therapeutics Inc

Atvērts

SektorsVeselības aprūpe

4.55 4.84

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.24

Max

4.73

Galvenie mērījumi
By Trading Economics
Ienākumi	-12M -27M
Pārdošana	-5.3M 663K
P/E Sektora vidējais	22.5 57.05
Peļņas marža	-3,998.492
Darbinieki	69
EBITDA	-13M -27M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+202.43% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 11. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-180M 964M
Iepriekšējā atvēršanas cena	-0.29
Iepriekšējā slēgšanas cena	4.55

Ziņu noskaņojums

By Acuity

50%

169 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

0.7658 / N/A Atbalsts un pretestība

CytomX Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. marts 23:15 UTC

Galvenie ziņu notikumi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026. g. 30. marts 22:36 UTC

Galvenie ziņu notikumi

Australian Government Rules Out Boots on the Ground in the Middle East

2026. g. 30. marts 22:13 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026. g. 30. marts 21:00 UTC

Peļņas

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026. g. 30. marts 20:15 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026. g. 30. marts 23:36 UTC

Tirgus saruna

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026. g. 30. marts 23:12 UTC

Tirgus saruna

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026. g. 30. marts 22:49 UTC

Tirgus saruna

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026. g. 30. marts 22:44 UTC

Tirgus saruna

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026. g. 30. marts 22:43 UTC

Tirgus saruna

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026. g. 30. marts 22:42 UTC

Tirgus saruna

South32 Should Go for Growth, Says New Bull -- Market Talk

2026. g. 30. marts 22:18 UTC

Tirgus saruna

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026. g. 30. marts 22:05 UTC

Tirgus saruna

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026. g. 30. marts 21:58 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026. g. 30. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026. g. 30. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026. g. 30. marts 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026. g. 30. marts 21:03 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026. g. 30. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 30. marts 20:09 UTC

Peļņas

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026. g. 30. marts 20:00 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Salīdzinājums

Cenas izmaiņa

CytomX Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

202.43% augšup

Prognoze 12 mēnešiem

Vidējais 13.67 USD 202.43%

Augstākais 17 USD

Zemākais 11 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 9 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CytomX Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

0.7658 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Noskaņojums

By Acuity

169 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.